303 related articles for article (PubMed ID: 19261608)
1. Depletion of Pleckstrin homology domain leucine-rich repeat protein phosphatases 1 and 2 by Bcr-Abl promotes chronic myelogenous leukemia cell proliferation through continuous phosphorylation of Akt isoforms.
Hirano I; Nakamura S; Yokota D; Ono T; Shigeno K; Fujisawa S; Shinjo K; Ohnishi K
J Biol Chem; 2009 Aug; 284(33):22155-22165. PubMed ID: 19261608
[TBL] [Abstract][Full Text] [Related]
2. Reduction of Raf kinase inhibitor protein expression by Bcr-Abl contributes to chronic myelogenous leukemia proliferation.
Takemura T; Nakamura S; Yokota D; Hirano I; Ono T; Shigeno K; Fujisawa S; Ohnishi K
J Biol Chem; 2010 Feb; 285(9):6585-94. PubMed ID: 20028985
[TBL] [Abstract][Full Text] [Related]
3. HOXA10 expression induced by Abl kinase inhibitors enhanced apoptosis through PI3K pathway in CML cells.
Sugimoto Y; Nakamura S; Okinaka K; Hirano I; Ono T; Shigeno K; Shinjo K; Ohnishi K
Leuk Res; 2008 Jun; 32(6):962-71. PubMed ID: 18190961
[TBL] [Abstract][Full Text] [Related]
4. Down-regulation of Thanatos-associated protein 11 by BCR-ABL promotes CML cell proliferation through c-Myc expression.
Nakamura S; Yokota D; Tan L; Nagata Y; Takemura T; Hirano I; Shigeno K; Shibata K; Fujisawa S; Ohnishi K
Int J Cancer; 2012 Mar; 130(5):1046-59. PubMed ID: 21400515
[TBL] [Abstract][Full Text] [Related]
5. EPS8 regulates proliferation, apoptosis and chemosensitivity in BCR-ABL positive cells via the BCR-ABL/PI3K/AKT/mTOR pathway.
Huang R; Liu H; Chen Y; He Y; Kang Q; Tu S; He Y; Zhou X; Wang L; Yang J; Wu A; Li Y
Oncol Rep; 2018 Jan; 39(1):119-128. PubMed ID: 29192326
[TBL] [Abstract][Full Text] [Related]
6. Functional phosphoproteomic analysis reveals cold-shock domain protein A to be a Bcr-Abl effector-regulating proliferation and transformation in chronic myeloid leukemia.
Sears D; Luong P; Yuan M; Nteliopoulos G; Man YK; Melo JV; Basu S
Cell Death Dis; 2010 Nov; 1(11):e93. PubMed ID: 21368869
[TBL] [Abstract][Full Text] [Related]
7. Growth of chronic myeloid leukemia cells is inhibited by infection with Ad-SH2-HA adenovirus that disrupts Grb2-Bcr-Abl complexes.
Peng Z; Luo HW; Yuan Y; Shi J; Huang SF; Li CL; Cao WX; Huang ZG; Feng WL
Oncol Rep; 2011 May; 25(5):1381-8. PubMed ID: 21369701
[TBL] [Abstract][Full Text] [Related]
8. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
Burchert A; Wang Y; Cai D; von Bubnoff N; Paschka P; Müller-Brüsselbach S; Ottmann OG; Duyster J; Hochhaus A; Neubauer A
Leukemia; 2005 Oct; 19(10):1774-82. PubMed ID: 16136169
[TBL] [Abstract][Full Text] [Related]
9. FAM168A participates in the development of chronic myeloid leukemia via BCR-ABL1/AKT1/NFκB pathway.
Liu X; Mai H; Jiang H; Xing Z; Peng D; Kong Y; Zhu C; Chen Y
BMC Cancer; 2019 Jul; 19(1):679. PubMed ID: 31291942
[TBL] [Abstract][Full Text] [Related]
10. Bone marrow-derived mesenchymal stromal cells promote resistance to tyrosine kinase inhibitors in chronic myeloid leukemia via the IL-7/JAK1/STAT5 pathway.
Zhang X; Tu H; Yang Y; Jiang X; Hu X; Luo Q; Li J
J Biol Chem; 2019 Aug; 294(32):12167-12179. PubMed ID: 31235520
[TBL] [Abstract][Full Text] [Related]
11. Role of BCR-ABL-Y177-mediated p27kip1 phosphorylation and cytoplasmic localization in enhanced proliferation of chronic myeloid leukemia progenitors.
Chu S; McDonald T; Bhatia R
Leukemia; 2010 Apr; 24(4):779-87. PubMed ID: 20200561
[TBL] [Abstract][Full Text] [Related]
12. Gadd45a deficiency accelerates BCR-ABL driven chronic myelogenous leukemia.
Mukherjee K; Sha X; Magimaidas A; Maifrede S; Skorski T; Bhatia R; Hoffman B; Liebermann DA
Oncotarget; 2017 Feb; 8(7):10809-10821. PubMed ID: 28086219
[TBL] [Abstract][Full Text] [Related]
13. Small GTPase RAB45-mediated p38 activation in apoptosis of chronic myeloid leukemia progenitor cells.
Nakamura S; Takemura T; Tan L; Nagata Y; Yokota D; Hirano I; Shigeno K; Shibata K; Fujie M; Fujisawa S; Ohnishi K
Carcinogenesis; 2011 Dec; 32(12):1758-72. PubMed ID: 21890458
[TBL] [Abstract][Full Text] [Related]
14. TOPK is regulated by PP2A and BCR/ABL in leukemia and enhances cell proliferation.
Uchida E; Suwa S; Yoshimoto R; Watanabe K; Kasama T; Miura O; Fukuda T
Int J Oncol; 2019 May; 54(5):1785-1796. PubMed ID: 30864683
[TBL] [Abstract][Full Text] [Related]
15. Propofol enhances BCR-ABL TKIs' inhibitory effects in chronic myeloid leukemia through Akt/mTOR suppression.
Tan Z; Peng A; Xu J; Ouyang M
BMC Anesthesiol; 2017 Sep; 17(1):132. PubMed ID: 28962554
[TBL] [Abstract][Full Text] [Related]
16. Growth inhibitory effect of dihydroartemisinin on Bcr/Abl+ chronic myeloid leukemia K562 cells involve AKT, ERK and NF-κB modulation.
Lee J; Zhang G; Wu X; Xu F; Zhou J; Zhang X
J Cancer Res Clin Oncol; 2012 Dec; 138(12):2095-102. PubMed ID: 22833150
[TBL] [Abstract][Full Text] [Related]
17. Selection of myeloid progenitors lacking BCR/ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein.
Carlo-Stella C; Dotti G; Mangoni L; Regazzi E; Garau D; Bonati A; Almici C; Sammarelli G; Savoldo B; Rizzo MT; Rizzoli V
Blood; 1996 Oct; 88(8):3091-100. PubMed ID: 8874208
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
[TBL] [Abstract][Full Text] [Related]
19. Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function.
Xiao M; Ai H; Li T; Rajoria P; Shahu P; Li X
Biochem Biophys Res Commun; 2016 Apr; 472(4):610-6. PubMed ID: 26966074
[TBL] [Abstract][Full Text] [Related]
20. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]